Literature DB >> 27260996

Heterotopic ossification of the long head of the triceps after reverse total shoulder arthroplasty.

Jia-Wei Kevin Ko1, Jeffrey D Tompson2, Daniel S Sholder3, Eric M Black4, Joseph A Abboud5.   

Abstract

BACKGROUND: Heterotopic ossification (HO) around shoulder arthroplasty is a frequent finding with unclear clinical relevance. This study evaluated the incidence, relevance, and predisposing factors of HO in the long head of the triceps tendon after reverse shoulder arthroplasty.
METHODS: Retrospective chart review was conducted to identify patients who had a reverse shoulder arthroplasty performed between 2008 and 2012. Patient demographics, implant types, and diagnoses were noted. Three fellowship-trained shoulder/elbow surgeons independently evaluated postoperative Grashey radiographs using a novel classification system.
RESULTS: Within a 164-patient cohort, the overall HO rate in the long head of the triceps tendon was 61.6%; 23.2% of osteophytes were considered impinging, 14.6% had notching, 14.0% were free-floating, and 3.0% appeared ankylosed. Although not statistically significant, revision surgery had a higher rate of HO (68.3%) compared with primary surgery (59.4%). There was no difference in HO rates between diagnoses or implant types. Male and female HO rates were 74.0% and 56.1%, respectively (P = .0304). Between patients with and without HO, forward elevation was 121° compared with 133° (P = .0087) and external rotation was 19° compared with 25° (P = .0266); however, HO size did not significantly affect motion.
CONCLUSIONS: Using our novel classification scheme, HO was a common finding in this series. Men had a higher rate of HO formation, and HO formation was associated with worse postoperative motion. Further study is needed to fully characterize the clinical implications of HO involving the long head of the triceps tendon and to explore potential preventive measures.
Copyright © 2016 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heterotopic ossification; impingement; notching; osteophyte; reverse shoulder arthroplasty; reverse total shoulder

Mesh:

Year:  2016        PMID: 27260996     DOI: 10.1016/j.jse.2016.03.006

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  6 in total

1.  Massive Heterotopic Ossification in the Subdeltoid Space after Shoulder Surgery and Symptomatic Improvement from Conservative Treatment: A Case Report.

Authors:  Tomoyuki Matsuba; Yukihiko Hata; Norio Ishigaki; Koichi Nakamura; Hiroyuki Kato
Journal:  Prog Rehabil Med       Date:  2019-11-13

2.  Delta Xtend reverse shoulder arthroplasty - Results at a minimum of five years.

Authors:  Craig M Ball
Journal:  Shoulder Elbow       Date:  2019-03-06

3.  Reverse total shoulder arthroplasty.

Authors:  Filippo Familiari; Jorge Rojas; Mahmut Nedim Doral; Gazi Huri; Edward G McFarland
Journal:  EFORT Open Rev       Date:  2018-02-28

4.  Surgical Management of Shoulder Heterotopic Ossification.

Authors:  Justin Hallock; Larry D Field
Journal:  Arthrosc Tech       Date:  2019-09-18

Review 5.  The modern reverse shoulder arthroplasty and an updated systematic review for each complication: part I.

Authors:  Sarav S Shah; Benjamin T Gaal; Alexander M Roche; Surena Namdari; Brian M Grawe; Macy Lawler; Stewart Dalton; Joseph J King; Joshua Helmkamp; Grant E Garrigues; Thomas W Wright; Bradley S Schoch; Kyle Flik; Randall J Otto; Richard Jones; Andrew Jawa; Peter McCann; Joseph Abboud; Gabe Horneff; Glen Ross; Richard Friedman; Eric T Ricchetti; Douglas Boardman; Robert Z Tashjian; Lawrence V Gulotta
Journal:  JSES Int       Date:  2020-09-07

Review 6.  Heterotopic Ossification: Clinical Features, Basic Researches, and Mechanical Stimulations.

Authors:  Yili Xu; Mei Huang; Wenzhen He; Chen He; Kaixuan Chen; Jing Hou; Min Huang; Yurui Jiao; Ran Liu; Nanyu Zou; Ling Liu; Changjun Li
Journal:  Front Cell Dev Biol       Date:  2022-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.